Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation.

BACKGROUND: Psoriasis is a chronic inflammatory disease that predominantly affects the skin. Adalimumab (HUMIRA(®), AbbVie, Maidenhead, UK), etanercept (Enbrel(®), Pfizer, New York, NY, USA) and ustekinumab (STELARA(®), Janssen Biotech, Inc., Titusville, NJ, USA) are the three biological treatments...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Health Technol Assess
Hauptverfasser: Duarte, Ana, Mebrahtu, Teumzghi, Goncalves, Pedro Saramago, Harden, Melissa, Murphy, Ruth, Palmer, Stephen, Woolacott, Nerys, Rodgers, Mark, Rothery, Claire
Format: Artigo
Sprache:Inglês
Veröffentlicht: NIHR Journals Library 2017
Schlagworte:
Research Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5694897/
https://ncbi.nlm.nih.gov/pubmed/29105621
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3310/hta21640
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge